TABLE 3.
Multivariate analysis of characteristics for early death among bone metastatic breast cancer patients.
| Characteristic | OR | 95% CI | p | |
|---|---|---|---|---|
| Lower limit | Upper limit | |||
| (Intercept) | 0.071 | 0.024 | 0.209 | <0.001 |
| Age | 1.025 | 1.021 | 1.029 | <0.001 |
| Sex | ||||
| Female | Reference | |||
| Male | 0.958 | 0.594 | 1.545 | 0.861 |
| Race | ||||
| American Indian/Alaska Native | Reference | |||
| Asian or Pacific Islander | 1.391 | 0.624 | 3.100 | 0.419 |
| Black | 1.423 | 0.646 | 3.134 | 0.381 |
| White | 1.284 | 0.588 | 2.803 | 0.531 |
| Unknown | 0.529 | 0.147 | 1.904 | 0.330 |
| Marital status | ||||
| Married (which includes common law) | Reference | |||
| Separated, divorced, or widowed | 1.145 | 1.011 | 1.296 | 0.033 |
| Single (never married) | 1.360 | 1.188 | 1.556 | <0.001 |
| Others | 0.977 | 0.780 | 1.223 | 0.838 |
| Geographic areas | ||||
| Metropolitan counties | Reference | |||
| Nonmetropolitan counties | 1.312 | 1.126 | 1.529 | 0.001 |
| Unknown | 2.914 | 0.724 | 11.734 | 0.132 |
| Laterality | ||||
| Bilateral, single primary | Reference | |||
| Left—origin of primary | 1.021 | 0.588 | 1.774 | 0.940 |
| Only one side—side unspecified | 0.379 | 0.142 | 1.009 | 0.052 |
| Paired site, but no information concerning laterality | 0.734 | 0.408 | 1.320 | 0.302 |
| Right—origin of primary | 1.037 | 0.597 | 1.801 | 0.897 |
| Brain metastasis | ||||
| No | Reference | |||
| Unknown | 0.901 | 0.662 | 1.226 | 0.507 |
| Yes | 2.326 | 1.962 | 2.757 | <0.001 |
| Liver metastasis | ||||
| No | Reference | |||
| Unknown | 1.107 | 0.773 | 1.586 | 0.578 |
| Yes | 2.821 | 2.514 | 3.165 | <0.001 |
| Lung metastasis | ||||
| No | Reference | |||
| Unknown | 1.057 | 0.778 | 1.437 | 0.723 |
| Yes | 1.510 | 1.352 | 1.687 | <0.001 |
| T stage | ||||
| T0 | Reference | |||
| T1 | 0.963 | 0.654 | 1.420 | 0.850 |
| T2 | 1.082 | 0.749 | 1.562 | 0.675 |
| T3 | 1.124 | 0.767 | 1.646 | 0.550 |
| T4 | 1.441 | 1.001 | 2.075 | 0.049 |
| TX | 1.272 | 0.895 | 1.806 | 0.179 |
| N stage | ||||
| N0 | Reference | |||
| N1 | 0.868 | 0.762 | 0.989 | 0.033 |
| N2 | 0.891 | 0.714 | 1.112 | 0.308 |
| N3 | 0.838 | 0.685 | 1.025 | 0.085 |
| NX | 1.159 | 0.983 | 1.366 | 0.079 |
| Histologic type | ||||
| Adenomas and adenocarcinomas | Reference | |||
| Ductal and lobular neoplasms | 0.843 | 0.697 | 1.021 | 0.080 |
| Epithelial neoplasms, NOS | 1.249 | 0.993 | 1.571 | 0.058 |
| Squamous cell neoplasms | 1.675 | 0.453 | 6.202 | 0.440 |
| Unspecified neoplasms | 1.552 | 1.135 | 2.122 | 0.006 |
| Others | 0.991 | 0.531 | 1.849 | 0.977 |
| Grade | ||||
| Grade I | 0.631 | 0.470 | 0.846 | 0.002 |
| Grade II | Reference | |||
| Grade III | 1.175 | 1.004 | 1.375 | 0.045 |
| Grade IV | 0.754 | 0.294 | 1.936 | 0.557 |
| Unknown | 1.158 | 1.009 | 1.328 | 0.037 |
| ER status | ||||
| Borderline/unknown | Reference | |||
| Negative | 0.795 | 0.507 | 1.248 | 0.318 |
| Positive | 0.351 | 0.229 | 0.537 | <0.001 |
| PR status | ||||
| Borderline/unknown | Reference | |||
| Negative | 1.679 | 1.096 | 2.571 | 0.017 |
| Positive | 1.106 | 0.726 | 1.684 | 0.640 |
| HER2 | ||||
| Borderline/unknown | Reference | |||
| Negative | 0.910 | 0.747 | 1.108 | 0.347 |
| Positive | 0.861 | 0.685 | 1.082 | 0.199 |
| Cancer-directed surgery | ||||
| No | Reference | |||
| Unknown | 0.373 | 0.223 | 0.623 | <0.001 |
| Yes | 0.298 | 0.246 | 0.361 | <0.001 |
| Radiation | ||||
| No/unknown | Reference | |||
| Yes | 0.623 | 0.553 | 0.702 | <0.001 |
| Chemotherapy | ||||
| No/unknown | Reference | |||
| Yes | 0.217 | 0.192 | 0.245 | <0.001 |
OR, odds ratio; CI, confident interval; SD, standard deviation; T, tumor; N, nodes, NOS, not otherwise specified; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2.